Penumbra (PEN) Net Cash Flow Growth (5y) (2019 - 2026)
Penumbra (PEN) Net Cash Flow Growth (5y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.33 Bn | 174.04 Bn | 6.27 Bn |
| 2 | Stryker | 128.11 Bn | 125.23 Bn | 3.81 Bn |
| 3 | Medtronic | 107.76 Bn | 98.54 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.95 Bn | 66.50 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.64 Bn | 43.97 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 28.43 Bn | 26.14 Bn | 1.98 Bn |
| 7 | Dexcom | 28.31 Bn | 27.20 Bn | 750.30 Mn |
| 8 | Smith & Nephew | 26.77 Bn | 26.19 Bn | - |
| 9 | Koninklijke Philips | 25.33 Bn | 22.21 Bn | 2.07 Bn |
| 10 | Penumbra | 12.53 Bn | 11.92 Bn | 253.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42.70% |
| Dec 31, 2025 | -68.57% |
| Sep 30, 2025 | -13.00% |
| Jun 30, 2025 | -6.62% |
| Mar 31, 2025 | 194.53% |
| Dec 31, 2024 | 25.96% |
| Sep 30, 2024 | -17.50% |
| Jun 30, 2024 | 40.78% |
| Mar 31, 2024 | 14.76% |
| Dec 31, 2023 | 26.74% |
| Sep 30, 2023 | -3.47% |
| Jun 30, 2023 | 19.78% |
| Mar 31, 2023 | 69.98% |
| Dec 31, 2022 | 25.04% |
| Sep 30, 2022 | 23.00% |
| Jun 30, 2022 | 19.93% |
| Mar 31, 2022 | -38.56% |
| Dec 31, 2021 | -15.78% |
| Sep 30, 2021 | -48.13% |
| Jun 30, 2021 | 66.07% |